16 Multiple Myeloma Clinical Trials in Seattle, WA (2026)

Q: How do I join a clinical trial in Seattle?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you.

Recruiting Multiple Myeloma Studies in Seattle

NCT07791862Recruiting

Familial Inflammatory Bowel Disease Early Risk

Brief Summary The aim of the FIBER study is to identify potential triggers associated with the later development of IBD (inflammatory bowel disease) based on baseline characteristics and biosamples (...

Seattle, WA7,000 participantsSeattle Children's Hospital

View Study Details

NCT05750498Recruiting

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will...

Seattle, WA800 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06149910Recruiting

Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, t...

Seattle, WA450 participantsAll4Cure

View Study Details

NCT05730036Recruiting

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

This study is researching an experimental drug called linvoseltamab, also called REGN5458. Linvoseltamab has previously been studied by itself (without other cancer drugs) in participants who had adv...

Seattle, WAPHASE3410 participantsRegeneron Pharmaceuticals

View Study Details

NCT05231629Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is mu...

Seattle, WAPHASE2300 participantsUniversity of Alabama at Birmingham

View Study Details

NCT06500884Recruiting

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preven...

Seattle, WAPHASE2210 participantsJanssen Research & Development, LLC

View Study Details

NCT06315179Recruiting

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort ...

Seattle, WA200 participantsSeattle Children's Hospital

View Study Details

NCT06896916Recruiting

Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease ac...

Seattle, WAPHASE1135 participantsAbbVie

View Study Details

NCT06140524Recruiting

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

This study is researching an investigational drug called linvoseltamab ("study drug") in participants at moderate risk of developing multiple myeloma (about 3 to 10% average annual risk), a group that...

Seattle, WAPHASE2116 participantsRegeneron Pharmaceuticals

View Study Details

NCT05956457Recruiting

PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma

This study will evaluate the feasibility of a digital health coaching program for adults with relapsed or refractory multiple myeloma (R/R MM). One hundred adults with R/R MM will be enrolled at The U...

Seattle, WANA100 participantsPack Health

View Study Details

NCT07104565Recruiting

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders....

Seattle, WAPHASE256 participantsIncyte Corporation

View Study Details

NCT07304154Recruiting

A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in partici...

Seattle, WAPHASE152 participantsKite, A Gilead Company

View Study Details

NCT05053607Recruiting

Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab

This descriptive study aims to evaluate the experience of adults with relapsed or refractory multiple myeloma receiving standard of care isatuximab-irfc through collection of quantitative, qualitative...

Seattle, WANA50 participantsPack Health

View Study Details

NCT07209371Recruiting

Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance

This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is on...

Seattle, WAPHASE250 participantsFred Hutchinson Cancer Center

View Study Details

NCT07181941Recruiting

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

This phase I/II trial evaluates the safety and feasibility of early, response-based dose reduction of linvoseltamab in the treatment of patients multiple myeloma that has come back after a period of i...

Seattle, WAPHASE130 participantsFred Hutchinson Cancer Center

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Seattle, WAPHASE120 participantsAdaptimmune

View Study Details

About Multiple Myeloma Clinical Trials in Seattle

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 16 multiple myeloma clinical trials recruiting participants in Seattle, WA. These studies are seeking a combined 9,979 participants. Research is being sponsored by Seattle Children's Hospital, Children's Hospital Medical Center, Cincinnati, All4Cure and 9 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Seattle — FAQ

Are there multiple myeloma clinical trials in Seattle?

Yes, there are 16 multiple myeloma clinical trials currently recruiting in Seattle, WA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Seattle?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Seattle research site will contact you about next steps.

Are clinical trials in Seattle free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Seattle studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 16 active trials in Seattle are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated September 1, 2026 from ClinicalTrials.gov